Pancreatic Cancer Clinical Trials in Chicago

Showing 121-140 of 150 trials

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

NCT00031837

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Anticoagulants such as dalteparin may help prevent blood clots in patients being treated with gemcitabine for unresectable or metastatic pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without dalteparin in treating patients who have unresectable or metastatic pancreatic cancer.

Pancreatic CancerThromboembolism

Gary Morrow400 participantsStarted Oct 2002

Mobile, Alabama, United States • Denver, Colorado, United States • Chicago, Illinois, United States +10 more locations

COMPLETEDPhase 22.2 miles

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

NCT00633789

The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment. Those in which it is unclear will be randomized to continue or withdraw treatment to determine whether that benefit is related to brivanib

Advanced Non-small Cell Lung CancerTransitional Cell CarcinomaSoft Tissue Sarcoma+2 more

Bristol-Myers Squibb597 participantsStarted Jun 2008

Chicago, Illinois, United States • Evanston, Illinois, United States • Baltimore, Maryland, United States +22 more locations

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Pancreatic Cancer Trials in Other Cities

(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer

Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer

3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

BMS-247550 in Treating Patients With Advanced Pancreatic Cancer

Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine

Pancreatic Cancer Serum and DNA Repository

Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction

A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer

APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Other Conditions in Chicago